Latest Global Expansion News

Merino & Co’s successful IPO has injected $6.35 million into the company, enabling a strategic expansion of manufacturing capacity and securing a new facility in Western Australia. The company is now poised to scale globally with automated production and enhanced distribution capabilities.

RocketBoots Limited has secured a contract extension with a major Australian retailer and raised $1.5 million to accelerate its international expansion, while advancing multiple multinational trials of its AI-powered SaaS platform.

RooLife Group (ASX: RLG) reported a striking 144% increase in sales revenue for Q2 FY2025, driven by the launch of new online stores across China, Hong Kong, Australia, and India. The company is investing heavily in product development and marketing to capitalize on booming health and wellness markets.

Oakridge International Limited reports a strong quarterly performance driven by increased contracted orders, strategic partnerships, and technological innovation, positioning the company for sustained growth into 2025.

Zimi Limited has secured $2.495 million through a capital raising, appointed new board members, and initiated cost-saving measures exceeding $400,000 annually, while navigating a compliance issue affecting sales to a major distributor.

Visioneering Technologies reported a mixed Q4 FY'24 with a slight revenue decline but stronger cash flow and expanding global footprint, underpinned by promising clinical trial data.

IODM Limited reported a robust 49.4% increase in Q2 FY25 cash receipts, driven by explosive growth in its UK Education segment and strategic onboarding of prestigious universities.

Adslot Ltd reports a robust Q2 FY25 with significant contract wins for its StoreFront platform and a 43% quarter-on-quarter increase in monetised transaction value, despite ongoing challenges in the Australian market.

ResMed Inc. posted a robust second quarter for fiscal year 2025, with revenue climbing 10% to $1.3 billion and operating profit soaring 52%, driven by strong demand for sleep and breathing health products and operational efficiencies.

Paradigm Biopharmaceuticals has secured FDA clearance for its phase 3 knee osteoarthritis trial and raised $16 million to fund its next clinical steps, positioning the company for a pivotal year ahead.

MyEco Group Ltd has reported a robust 32% increase in sustainable product sales for Q2 FY25, driven by a remarkable 156% jump in MyEco branded product sales. Despite negative operating cash flow due to inventory build-up, the company is poised for continued growth in the second half of the fiscal year.

Opyl Limited's Q2 FY25 update reveals robust progress through key partnerships, a new AI Biotech Fund launch, and strengthened financial footing, positioning the company for expanded influence in clinical trial optimisation.